Sengenics, Parkway Partner on Genetic Testing in Singapore | GenomeWeb

NEW YORK (GenomeWeb News) – Sengenics and Parkway Laboratory Services have entered into a partnership to offer genetics tests in Singapore, Sengenics said on Thursday.

The deal focuses on Sengenics' CardioSure heart disease test and Sequenom's MaterniT21 Plus non-invasive prenatal diagnostic test. The CardioSure test, Sengenics said, is based on a concept of "Asianized Diagnostics" to include disease biomarkers from Asian ethnic groups as well as those from Caucasian and African populations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.